原料药 API

The first nonsteroidal mineralocorticoid receptor antagonist (nsMRA), filling an anti-inflammatory and anti-fibrotic gap in diabetic kidney disease and recommended by major guidelines, a clearly incremental new product.

A core endocrine therapy for prostate cancer requiring continuous long-term dosing, ensuring stable annual API demand and well suited to long-term FSO supply arrangements.

A leading oral targeted therapy in autoimmunity spanning rheumatology, dermatology and gastroenterology, with strong and definable volume upside.

A topical non-fluoroquinolone quinolone targeting resistant Gram-positive bacteria; its pediatric and local-use profile offers differentiation in OTC and pediatric markets.

The world's first approved MASH therapy, opening a vast untreated blue-ocean; numerous follow-on pipelines will scale API demand alongside the entire class.

A next-generation potassium-competitive acid blocker (P-CAB) with faster onset and no food effect versus PPIs, the upgrade direction for acid-related disease.

The first approved non-hormonal therapy for menopausal hot flashes, with broad scope to replace hormone therapy, a large and long-unmet patient population.

A mainstream pet parasiticide with single-dose long protection; rising global pet-care spending sustains growing animal-health API demand.

A core oral pet parasiticide with good palatability and monthly dosing, often combined with milbemycin oxime, enabling fixed-combination product lines.

The only isoxazoline expanded into human ophthalmology (demodex blepharitis), combining a steady animal-health base with a human-use upside option.

One of several same-class agents, suitable as a combination supply within an animal-health portfolio to meet customers' generic and differentiated sourcing needs.

The first oral complement-factor-B inhibitor, converting PNH from infusion to oral therapy and expanding into nephrology, a high-value rare-disease molecule.

Addresses high-unmet need in post-transplant GVHD with a clear mechanism and limited competition, well suited to registration partnerships with transplant centers.

An oral single-dose agent with a wholly new mechanism against antimicrobial-resistant gonorrhea, a WHO-priority AMR direction with clear public-health procurement demand.

A capsid-binding inhibitor of rhinovirus that can reduce hospitalizations from COPD/asthma exacerbations, a scarce causal-therapy attempt in respiratory care.

A TGF-beta pathway inhibitor valuable both as an immuno-oncology combination component and in fibrosis, a dual-track development asset.

A broad-spectrum fluoroquinolone with extensive clinical experience and controllable cost, suited as a mature generic supply for regional markets.

A novel nucleoside reverse-transcriptase translocation inhibitor (NRTTI) with long-acting dosing, the core evolution of HIV treatment and prevention, high strategic value.

The first novel-mechanism inhaled COPD maintenance therapy in over a decade, combining bronchodilation and anti-inflammation, filling the gap after triple therapy.

A China-originated ALK inhibitor with globally competitive efficacy and safety, a mature asset for domestic innovative-drug export and licensing.

An ATR inhibitor targeting the DNA-damage-repair pathway, a hot combination strategy with chemo-radiotherapy and PARP inhibitors, strong pipeline extensibility.

An NS5B nucleotide analog with pangenotypic activity and a high resistance barrier, an important component of HCV combination and retreatment regimens.

A second-generation XPO1 inhibitor with improved tolerability over the first generation, offering a clear substitution opportunity in elderly AML/MDS.

A voltage-gated sodium-channel modulator for epilepsy; antiepileptic demand is stable in emerging markets, suited as a long-term mature product reserve.